A retroviral promoter is sufficient to convert proto-src to a transforming gene that is distinct from the src gene of Rous sarcoma virus.

Zhou, Hong; Duesberg, Peter H.

doi:10.1073/pnas.87.23.9128

Cited by 13 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infection of cells, with one particle of Rous sarcoma virus containing a single transforming gene can result in tumor production in vivo (14) or transformed focus production in vitro (15), but that capability is due to the presence of a strong viral promoter for expression of that gene (16). Transfection of NIH 3T3 cells with an activated ras gene from a human cancer advances their state of transformation (17), but that is because the NIH 3T3 cells were already partially transformed (18).…”

Section: Complexity Of Genetic Changes In Human Cancermentioning

confidence: 99%

Saturation Density of Skin Fibroblasts as a Quantitative Screen for Human Cancer Susceptibility

Rubin

2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Genomic analysis of human cancers reveals a large number of genetic changes per cell that presumably underlie development of the disease. The complexity of these changes that differ from one type of cancer to the other and from patient to patient with the same type of cancer raises questions about the feasibility of genomic analysis as an indicator of susceptibility to cancer. However, skin fibroblasts (SF) from individuals in families with heritable forms of cancer, and from cancer-bearing individuals, show correlation with a significant increase in saturation density (SD), as well as other neoplasia-related properties. Procedures are described for amplifying and quantifying differences in SD on the basis of studies of spontaneous transformation in the NIH 3T3 line of mouse fibroblasts. It is proposed that such procedures be evaluated as quantitative screens for susceptibility to cancer in the general population. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2366-72)

show abstract